Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled ...

LOS ANGELES, CA / ACCESS Newswire / March 10, 2026 / Today Technomark Life Sciences ( and MAX BioPharma ( announced their collaboration in the development of MAX BioPharma’s oxysterol drug candidate, ...

Nanomedicine is rapidly transforming the landscape of cancer treatment through the development of advanced drug-delivery carriers. Despite notable progress ...

Organoids, assembloids, and organ-on-a-chip technologies represent transformative advances in the fields of drug discovery, precision medicine, and ...

C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. Click for my latest analysis of CCCC stock.

This enables HSA to contribute to advancing global healthcare while keeping healthcare safe and effective. Read more at straitstimes.com. Read more at straitstimes.com.

Thermo Fisher Scientific Inc. (NYSE: TMO) is one of the best stocks that will always grow.

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapiesNTZ is being advanced ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...